Biotechs targeting cancer, immunology likely to draw buyout bids

07/13/2011 | Reuters

Biotech companies that specialize in drugs for cancer, immune system diseases and brain conditions are likely to become attractive acquisition targets for Big Pharma, said investment bankers and other industry experts. Among such firms are Seattle Genetics, which has a drug candidate for two rare types of blood cancer, and Biogen Idec, which has multiple sclerosis drugs on the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ